Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: A systematic review of the epidemiology of hepatitis E virus in Africa

Authors: Jong-Hoon Kim, Kenrad E. Nelson, Ursula Panzner, Yogita Kasture, Alain B. Labrique, Thomas F. Wierzba

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Excerpt

In this letter, we wish to correct errors in the previously published article [1]. Although the errors do not change the main results and conclusions described in the abstract of the original article, we believe providing the correct information is important. The major correction is about the genotype distribution of HEV in Africa. In the original article, we indicated that genotype 3 is rare and less commonly found than genotype 2 while genotype 1 is the most prevalent. The correct information is, however, that genotypes 2 and 3 were identified at a similar frequency while genotype 1 was the most prevalent. This error arose because the genotypes of HEV identified in seven Nigerian adults [89] were mistaken to be 2, when their actual genotype was 3. In what follows, we revised the relevant section named “Genotype prevalence” on page 5 of the original article and the relevant table and figure (i.e., Table 5 and Fig. 2).
Table 1
Seroprevalence of anti-HEV antibodies in Africa. Seroprevalence varies by country and by subpopulation and studies were done under different conditions (e.g., sample size, demographics, and different diagnostic methods). Age of the sample is provided as mean (range or ± standard deviation, if available)
Country
% sero-prevalence
Sample demographics
Sample size
Year of sampling
Diagnostic methods
Source
Burkina Faso
19.1
Blood donors
178
2010-12
IgG
[29]
 
11.6
Pregnant women
189
2010-12
IgG
[29]
Burundi
14.0
Adults without chronic liver disease, 44.7 yrs old (±13.5)
129
1986
Total Ig
[30]
Cameroon
14.2
HIV-infected adults, 38.1 yrs old (±11.3)and
289
2009-10
IgG
[32]
 
2.0
HIV-infected children, 8.3 yrs old (±7.5)
100
2009-10
IgG
[32]
CARa
24.2
Patients attending the center for sexually transmitted diseases
157
1995b
Total Ig
[33]
Djibouti
13.0
Male peacekeepers in Haiti, 31.2 yrs old
112
1998b
Total Ig
[42]
Egypt
84.3
Pregnant women, 24 yrs old (16-48)
2,428
1997-2003
Total Ig
[55]
 
80.1
Patients with chronic liver disease, 48 yrs old (23-62)
518
2000-2
IgG
[57]
 
67.6
Residents of two rural villages, 24.5 and 26.5 yrs, respectively
10,156
1997
Total Ig
[54]
 
58.6
Asymptomatic pregnant women, ~33 yrs old
116
2009
IgG
[58]
 
56.4
Residents of a semi-urban village, 1-67 yrs old
140
1993
Total Ig
[51]
 
54.1
Four waste water treatment plant male workers, 20-60 yrs old
205
1998-9
IgG
[116]
 
51.2
Waste water treatment plant workers, 47.1 yrs old
43
2011b
Total Ig
[60]
 
50.6
Waste water treatment plant workers, 20-60 yrs old
233
2000b
Total Ig
[61]
 
45.3
Blood donors, 18-45 yrs old
95
1998b
IgG
[52]
 
39.6
Haemodialysis patients, 8-20 yrs old
96
1998b
IgG
[52]
 
38.9
Healthy females, 21.8 yrs old (16-25)
95
1995
IgG
[50]
 
17.2
Residents of a hamlet, 20.9 yrs old (<1-95)
1259
1992
IgG
[49]
 
0.0
Healthy controls, 20–60 yrs old
96
1998-9
IgG
[116]
Gabon
14.2
Pregnant women, 24.6 yrs old (14-44)
840
2005, 2007
IgG
[73]
 
0.0
Villagers, 29 yrs old (2-80)
35
1991-2
Total Ig
[72]
Ghana
45.3
Adult HIV patients, 40 yrs old (±9.6)
402
2008-10
IgG
[32]
 
38.1
Pig handlers, 36.5 yrs old (12-65)
105
2009b
Total Ig
[77]
 
34.8
Pig handlers, 32.9 yrs old (15-70)
353
2008
Total Ig
[75]
 
28.7
Pregnant women, 28.9 yrs old (13-42)
157
2008
Total Ig
[78]
 
4.6
Blood donors
239
2012b
IgG
[76]
 
4.4
6-18 yr olds
803
1993
Total Ig
[74]
Madagascar
14.1
Slaughterhouse workers
427
2008-9
Total Ig
[81]
Morocco
8.5
Blood donors
200
2000-1
IgG
[85]
 
2.2
men (n = 232) and women (n = 259), 27.7 yrs old (±5.9)
491
1995b
IgG
[84]
Nigeria
94.0
Control healthy adults (n = 44)
44
2008-9
Total Ig
[90]
 
43.0
Health care workers
88
2008-9
Total Ig
[90]
 
13.4
Healthy and sick people, 29.8 yrs old (3-72)
186
2007
Total Ig
[91]
Sierra Leone
7.6
Primary school children, 6-12 yrs old
66
1998b
IgG
[139]
South Africa
10.7
Urban (n = 407) and rural (n = 360) blacks, 42 yrs old (18-85)
767
1996b
Total Ig
[98,117]
 
2.6
Medical students
227
1992
Total Ig
[97]
 
1.8
Canoeists who have been regularly exposed to waste water
555
1992
Total Ig
[97]
Tanzania
6.6
Women, 32.1 yrs old (15-45)
212
1996
Total Ig
[114]
 
0.2
Healthy adults, 30.3 yrs old
403
1992
Total Ig
[112]
 
0.0
Women
180
1995
Total Ig
[113]
Tunisia
46.0
Healthy persons, > 60 yrs old
100
1991
IgG
[106]
 
29.5
Children with chronic haematological diseases
34
1996
IgG
[106]
 
28.9
Polytransfused patients; adults (n = 59, 34.8 yrs old [20-61]) and children (n = 48, 7.3 yrs old [1-15])
107
2008-9
IgG
[107]
 
22.0
Healthy blood donors, < 40 yrs old
100
1996
IgG
[106]
 
12.1
Pregnant women, 30.1 yrs old (17-52)
404
2008-9
IgG
[108]
 
10.0
Healthy controls; blood donors (n = 100, 31.3 yrs old [20–58])
and children, (n = 60, 7.9 yrs old [1–15])
160
2008-9
IgG
[107]
 
5.4
Blood donors, 32.6 yrs old (± 8.6)
687
2007-8
Total Ig
[109]
 
4.3
Healthy persons, 20.7 yrs old (16-25)
1,505
2008b
IgG
[110]
Zambia
40.6c
Urban adults, 18–64 yrs old
106
1999
IgG
[115]
 
16.0
Urban children, 1–15 yrs old
194
2011
IgG
[115]
aCAR; Central African Republic
bThe year of the publication
cThe original study reports 42%, but the actual figures indicate that 43 out of 106 specimens are positive; 43/106 = 0.4056
Table 2
Sporadic cases caused by hepatitis E virus in Africa. Proportion of sporadic hepatitis cases attributable to HEV varies by country and by subpopulation and studies were done under different conditions (e.g., sample size, demographics, and different diagnostic methods). Age of the sample is provided as mean (range or ± standard deviation, if available)
Country
% sero-positivity
Case demographics
No. of cases
Year of sampling
Diagnostic methods
Source
Chad
48.8
Acute or fulminant hepatitis patients, 4-64 yrs old
41
1993
IgM
[36]
 
20.0a
Sporadic cases
17
1994
RT-PCRb
[27]
Djibouti
58.5
Acute hepatitis patients, 21.8 yrs old (2-65)
65
1992-3
IgM
[41]
Egypt
24.2
Jaundiced patients, 1-73 yrs old
202
1993
IgM
[46]
 
22.2
Jaundiced children, 5 yrs old (1-11)
261
1990
IgM
[70]
 
21.7
Acute hepatitis patients, 26.6 yrs old (18-60)
143
1993-4
IgM
[71]
 
20.2
Acute viral hepatitis patients, 8 yrs old
287
2006-8
IgM
[62]
 
17.9
Acute hepatitis patients, 15.7 (± 14.9) yrs old
235
2007-8
IgM or > = 3-fold rise in IgG
[69]
 
17.2
Children with elevated level (two-fold or more) of AST and ALT
64
2006d
IgM
[47]
 
15.7
Acute hepatitis patients, 15.9 yrs old (1-65)
235
2007-8
IgM
[63]
 
15.1
Children with acute jaundice, 6.4 yrs old (1-13)
73
1987-8
IgM
[45]
 
12.5
Patients with acute hepatitis, 20.2 yrs old (4-65)
200
2001-2
IgM
[64]
 
6.0
Children with minor hepatic ailments, 6 mo-10 yrs
100
2004-5
IgM
[65]
 
5.0
Patients with acute on chronic liver failure, 46.4 yrs old
100
2009-10
IgM
[66]
 
2.1
Acute viral hepatitis patients, 25 yrs old (2-77)
47
2002-5
IgM
[76]
 
2.0
Hepatitis patients, 5.4 yrs old (1.5-15)
50
2007
RT-PCR
[48]
Ethiopia
45.6
Acute viral hepatitis patients with NANB
79
1988-91
FABAd
[43]
 
31.8
Non-pregnant women with acute viral hepatitis, 30 yrs old
22
1988-91
FABA
[6]
 
67.9
Pregnant women with acute viral hepatitis, 26 yrs old
28
1988-91
FABA
[6]
Mayotte
100.0
Patients with acute jaundice, 46 yrs old
1
2009
IgM
[82]
Nigeria
70.0
Male patients with acute hepatitis, 25-33 yrs old
10
1997-8
RT-PCR
[89]
Senegal
20.0
Patients with jaundice
30
1992c
IgM
[93]
 
10.2
Patients with viral hepatitis
49
1993c
IgM
[92]
Somalia
61.1
Native Somalis and displaced Ethiopian patients with acute hepatitis, 7-90 yrs old
36
1992-3
IgM
[96]
Sudan
5.4
Patients with fulminant hepatic failure, 38 yrs old (19-75)
37
2003-4
IgM
[103]
 
59.0
Children with acute clinical jaundice, ≤14 yrs old
39
1987-8
IgM
[118]
a20% was extrapolated from the results of RT-PCR of 5 samples out of total 17 cases
bReverse transcription polymerase chain reaction
cThe year of the publication
dFABA; fluorescent antibody blocking assay, which is claimed to detect acute infection, not but past infection
Table 5
Genotype distribution from African HEVs
Genotype
Country
Year of sampling
Sample
RNA region tested
Source
1
CARa
2002
One fecal sample from an outbreak
NAb
[34]
 
Chad
1984
A patient with hepatitis E
Complete genome
[28]
   
2004
Five isolates from an outbreak
ORFc2 (363 ntd)
[35]
 
Egypt
1993
Acute hepatitis patients
ORF1 (location: 55-320)
[46]
   
2006-8
Acute hepatitis patients
ORF1
[62]
   
2012e
Sixteen isolates from acute hepatitis patients
ORF2 (189 nt)
[124]
 
Namibia
1983
Nine isolates from an outbreak in Kavango
ORF2 (296 nt), 3 (188 nt)
[88]
 
Sudan
2004
Twenty three isolates from an outbreak
ORF2 (363 nt)
[35]
 
Uganda
2007
Internally displaced persons camp
NA
[123]
   
2008
Twenty four isolates from an outbreak
NA
[119]
2
CAR
2002
Three fecal samples from an outbreak
NA
[34]
 
Chad
2004
Four isolates from an outbreak
ORF2 (363 nt)
[35]
 
Namibia
1995
Four isolates from NANB outbreak in Rundu
ORF2 (451 nt near 3'-end)
[87]
3
Nigeria
2000e
Ten adult acute hepatitis patients
ORF1, 2 (3'-end)
[89]
 
Egypt
2007
One 9 year-old acute hepatitis patient
ORF1, 2, 2/3
[48]
 
Mayotte
2009
One French acute hepatitis patient (46 yr old)
ORF2 (288 nt)
[82]
 
Madagascar
2009
Slaughter house workers
ORF2,3 (1000 nt)
[81]
aCAR; Central African Republic
bNA; not available
cORF; open reading frame
dnt; nucleotides
ePublication year
Literature
1.
go back to reference Kim J-H, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infectious Diseases. 2014;14:308.CrossRefPubMedPubMedCentral Kim J-H, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infectious Diseases. 2014;14:308.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: A systematic review of the epidemiology of hepatitis E virus in Africa
Authors
Jong-Hoon Kim
Kenrad E. Nelson
Ursula Panzner
Yogita Kasture
Alain B. Labrique
Thomas F. Wierzba
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2274-3

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.